Skip to content

Advertisement

Articles

Page 2 of 32

  1. Content type: Review article

    Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer the...

    Authors: Robert D. Leone and Leisha A. Emens

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:57

    Published on:

  2. Content type: Review

    During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific ...

    Authors: Alexander Shimabukuro-Vornhagen, Philipp Gödel, Marion Subklewe, Hans Joachim Stemmler, Hans Anton Schlößer, Max Schlaak, Matthias Kochanek, Boris Böll and Michael S. von Bergwelt-Baildon

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:56

    Published on:

  3. Content type: Research article

    Pixatimod (PG545) is a novel clinical-stage immunomodulatory agent capable of inhibiting the infiltration of tumor-associated macrophages (TAMs) yet also stimulate dendritic cells (DCs), leading to activation ...

    Authors: Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang and Keith Dredge

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:54

    Published on:

  4. Content type: Case report

    The treatment options for metastatic malignant melanoma have drastically changed recently,including the increased use of immunotherapeutic agents that offer significant responses. Accordingly, it hasbecome com...

    Authors: Joseph I. Clark, Shams Bufalino, Shruti Singh and Ewa Borys

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:53

    Published on:

  5. Content type: Research article

    Oncolytic viruses are currently experiencing accelerated development in several laboratories worldwide, with some forty-seven clinical trials currently recruiting. Many oncolytic viruses combine targeted cytot...

    Authors: Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy and Len W. Seymour

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:55

    Published on:

  6. Content type: Case report

    Immune checkpoint inhibitors (ICI) target T cell inhibitory pathways that are responsible for cancer tolerance by down-modulating immune functions. ICI have revolutionized patients care with lung cancer. Never...

    Authors: Léa Paolini, Caroline Poli, Simon Blanchard, Thierry Urban, Anne Croué, Marie-Christine Rousselet, Sarah Le Roux, Nathalie Labarrière, Pascale Jeannin and José Hureaux

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:52

    Published on:

  7. Content type: Research article

    Corticosteroids are routinely utilized to alleviate edema in patients with intracranial lesions and are first-line agents to combat immune-related adverse events (irAEs) that arise with immune checkpoint block...

    Authors: Amber J. Giles, Marsha-Kay N. D. Hutchinson, Heather M. Sonnemann, Jinkyu Jung, Peter E. Fecci, Nivedita M. Ratnam, Wei Zhang, Hua Song, Rolanda Bailey, Dionne Davis, Caitlin M. Reid, Deric M. Park and Mark R. Gilbert

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:51

    Published on:

  8. Content type: Research article

    The clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor t...

    Authors: Edwin R. Parra, Pamela Villalobos, Carmen Behrens, Mei Jiang, Apar Pataer, Stephen G. Swisher, William N. William Jr, Jiexin Zhang, Jack Lee, Tina Cascone, John V. Heymach, Marie-Andrée Forget, Cara Haymaker, Chantale Bernatchez, Neda Kalhor, Annikka Weissferdt…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:48

    Published on:

  9. Content type: Hypothesis

    Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of indivi...

    Authors: Tolga Turan, Deepti Kannan, Maulik Patel, J. Matthew Barnes, Sonia G. Tanlimco, Rongze Lu, Kyle Halliwill, Sarah Kongpachith, Douglas E. Kline, Wouter Hendrickx, Alessandra Cesano, Lisa H. Butterfield, Howard L. Kaufman, Thomas J. Hudson, Davide Bedognetti, Francesco Marincola…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:50

    Published on:

  10. Content type: Review

    Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to ...

    Authors: Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar and Richard Tuli

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:46

    Published on:

  11. Content type: Research article

    TGFβ signaling plays a pleotropic role in tumor biology, promoting tumor proliferation, invasion and metastasis, and escape from immune surveillance. Inhibiting TGFβ’s immune suppressive effects has become of ...

    Authors: Rikke B. Holmgaard, David A. Schaer, Yanxia Li, Stephen P. Castaneda, Mary Y. Murphy, Xiaohong Xu, Ivan Inigo, Julie Dobkin, Jason R. Manro, Philip W. Iversen, David Surguladze, Gerald E. Hall, Ruslan D. Novosiadly, Karim A. Benhadji, Gregory D. Plowman, Michael Kalos…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:47

    Published on:

  12. Content type: Correction

    Unfortunately, after publication of this article [1], it was noticed that corrections to the legends of Figs. 1 and 2 were not correctly incorporated. The correct legends can be seen below.

    Authors: Yiwen Li, Carmine Carpenito, George Wang, David Surguladze, Amelie Forest, Maria Malabunga, Mary Murphy, Yiwei Zhang, Andreas Sonyi, Darin Chin, Douglas Burtrum, Ivan Inigo, Anthony Pennello, Leyi Shen, Laurent Malherbe, Xinlei Chen…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:45

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:31

  13. Content type: Position article and guidelines

    Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs ...

    Authors: Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:44

    Published on:

  14. Content type: Case report

    Patients with metastatic Merkel cell carcinoma (mMCC) who experience disease progression on immunotherapy have limited additional standard options. Given evidence of synergism between radiation therapy (RT) an...

    Authors: Melody J. Xu, Susan Wu, Adil I. Daud, Siegrid S. Yu and Sue S. Yom

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:43

    Published on:

  15. Content type: Research article

    Extrapulmonary small cell carcinomas (ESCC) are rare but aggressive tumors. Relapses are common despite treatment with chemotherapy and/or radiotherapy. Prospective data for treatment of ESCC are lacking; trea...

    Authors: Mohammed Salhab, Yazan Migdady, Melanie Donahue, Yiqin Xiong, Karen Dresser, William Walsh, Benjamin J. Chen and James Liebmann

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:42

    Published on:

  16. Content type: Research article

    Adoptive cell transfer (ACT) is a promising cancer immunotherapeutic strategy that remains ineffective for a large subset of patients. ACT with memory CD8+ T cells (Tmem) has been shown to have superior efficacy ...

    Authors: Amanda Contreras, Megan V. Beems, Andrew J. Tatar, Siddhartha Sen, Prakrithi Srinand, M. Suresh, Tahra K. Luther and Clifford S. Cho

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:41

    Published on:

  17. Content type: Research article

    Immune checkpoint inhibiting antibodies were introduced into routine clinical practice for cancer patients. Checkpoint blockade has led to durable remissions in some patients, but may also induce immune-relate...

    Authors: Heinz Läubli, Catharina Balmelli, Lukas Kaufmann, Michal Stanczak, Mohammedyaseen Syedbasha, Dominik Vogt, Astrid Hertig, Beat Müller, Oliver Gautschi, Frank Stenner, Alfred Zippelius, Adrian Egli and Sacha I. Rothschild

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:40

    Published on:

  18. Content type: Research article

    Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patie...

    Authors: Michael Lattanzi, Joseph Han, Una Moran, Kierstin Utter, Jeremy Tchack, Rachel Lubong Sabado, Russell Berman, Richard Shapiro, Hsin-Hui Huang, Iman Osman, Nina Bhardwaj and Anna C. Pavlick

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:38

    Published on:

  19. Content type: Review

    Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (F...

    Authors: Young Kwang Chae, Ayush Arya, Wade Iams, Marcelo R. Cruz, Sunandana Chandra, Jaehyuk Choi and Francis Giles

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:39

    Published on:

  20. Content type: Research article

    Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The mechanisms of action for T-VEC and checkpoint inhibit...

    Authors: Lillian Sun, Pauline Funchain, Jung Min Song, Patricia Rayman, Charles Tannenbaum, Jennifer Ko, Michael Mcnamara, C. Marcela Diaz-Montero and Brian Gastman

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:36

    Published on:

  21. Content type: Review article

    The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatell...

    Authors: Michael M. Boyiadzis, John M. Kirkwood, John L. Marshall, Colin C. Pritchard, Nilofer S. Azad and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:35

    Published on:

  22. Content type: Research article

    Immune checkpoint inhibitors (ICPIs) are gaining increasing popularity as an efficacious treatment for advanced malignancies. ICPI treatment can be complicated by diarrhea and colitis. Systemic steroids are th...

    Authors: Yinghong Wang, Hamzah Abu-Sbeih, Emily Mao, Noman Ali, Faisal Shaukat Ali, Wei Qiao, Phillip Lum, Gottumukkala Raju, Gladis Shuttlesworth, John Stroehlein and Adi Diab

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:37

    Published on:

  23. Content type: Research article

    The adoptive transfer of T cells redirected to tumor via chimeric antigen receptors (CARs) has produced clinical benefits for the treatment of hematologic diseases. To extend this approach to breast cancer, we...

    Authors: Pradip Bajgain, Supannikar Tawinwung, Lindsey D’Elia, Sujita Sukumaran, Norihiro Watanabe, Valentina Hoyos, Premal Lulla, Malcolm K. Brenner, Ann M. Leen and Juan F. Vera

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:34

    Published on:

  24. Content type: Research article

    Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive ...

    Authors: Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Devin Dressman, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Moachun Qin, Yirong Wang, Felicia L. Lenzo, Angela Omilian, Wiam Bshara, Matthew Zibelman…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:32

    Published on:

  25. Content type: Case report

    Human papillomavirus-related small cell carcinoma of the head and neck is an extremely rare, aggressive subtype with poor outcomes. Therapeutic options are limited and are largely adopted from small cell lung ...

    Authors: Won Jin Ho, Lisa Rooper, Sarah Sagorsky and Hyunseok Kang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:33

    Published on:

  26. Content type: Research article

    Modulation of the PD-1/PD-L1 axis through antagonist antibodies that block either receptor or ligand has been shown to reinvigorate the function of tumor-specific T cells and unleash potent anti-tumor immunity...

    Authors: Yiwen Li, Carmine Carpenito, George Wang, David Surguladze, Amelie Forest, Maria Malabunga, Mary Murphy, Yiwei Zhang, Andreas Sonyi, Darin Chin, Douglas Burtrum, Ivan Inigo, Anthony Pennello, Leyi Shen, Laurent Malherbe, Xinlei Chen…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:31

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2018 6:45

  27. Content type: Research article

    Standard-of-care therapies for treating pediatric medulloblastoma have long-term side effects, even in children who are cured. One emerging modality of cancer therapy that could be equally effective without su...

    Authors: Anandani Nellan, Christopher Rota, Robbie Majzner, Cynthia M. Lester-McCully, Andrea M. Griesinger, Jean M. Mulcahy Levy, Nicholas K. Foreman, Katherine E. Warren and Daniel W. Lee

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:30

    Published on:

  28. Content type: Research article

    Receptors specific for the sugar N-acetylgalactosamine (GalNAc) include the human type II, C-type lectin receptor macrophage galactose-type lectin/C-type lectin receptor family member 10A (MGL/CLEC10A/CD301) that...

    Authors: Laura L. Eggink, Katherine F. Roby, Robert Cote and J. Kenneth Hoober

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:28

    Published on:

  29. Content type: Research article

    Microsatellite instability (MSI) is now being used as a sole biomarker to guide immunotherapy treatment for men with advanced prostate cancer. Yet current molecular diagnostic tests for MSI have not been evalu...

    Authors: Jennifer A. Hempelmann, Christina M. Lockwood, Eric Q. Konnick, Michael T. Schweizer, Emmanuel S. Antonarakis, Tamara L. Lotan, Bruce Montgomery, Peter S. Nelson, Nola Klemfuss, Stephen J. Salipante and Colin C. Pritchard

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:29

    Published on:

  30. Content type: Case report

    Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up. ...

    Authors: Zoë Blake, Douglas K. Marks, Robyn D. Gartrell, Thomas Hart, Patti Horton, Simon K. Cheng, Bret Taback, Basil A. Horst and Yvonne M. Saenger

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:25

    Published on:

  31. Content type: Research article

    One of today’s greatest hurdles for cancer immunotherapy is the absence of information regarding which tumor antigens are already recognized by patients receiving immunotherapies, and whether those therapies t...

    Authors: Tyler W. Hulett, Shawn M. Jensen, Phillip A. Wilmarth, Ashok P. Reddy, Carmen Ballesteros-Merino, Michael E. Afentoulis, Christopher Dubay, Larry L. David and Bernard A. Fox

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:27

    Published on:

  32. Content type: Case report

    Immunotherapies targeting the PD-1 checkpoint pathway have recently gained regulatory approval in numerous cancer types. With the widespread use of immune checkpoint therapies, varying patterns of responses an...

    Authors: Randy F. Sweis, Yuanyuan Zha, Lomax Pass, Brian Heiss, Tara Chongsuwat, Jason J. Luke, Thomas F. Gajewski and Russell Szmulewitz

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:24

    Published on:

  33. Content type: Research article

    Immune checkpoint inhibitors targeting PD-1/PD-L1 pathway demonstrated promising activities in variety of malignancies, however little is known regarding their efficacy in adults aged ≥65 years.

    Authors: Rawad Elias, Anita Giobbie-Hurder, Nadine Jackson McCleary, Patrick Ott, F. Stephen Hodi and Osama Rahma

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:26

    Published on:

  34. Content type: Research article

    Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune c...

    Authors: Isaac S. Chan, Shailender Bhatia, Howard L. Kaufman and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:23

    Published on:

  35. Content type: Case report

    Pembrolizumab is an anti–programmed death 1 (PD-1) receptor monoclonal antibody that has shown activity as second line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). Immune-related advers...

    Authors: Fanny Zulay Acero Brand, Nicolas Suter, Jean-Philippe Adam, Bernard Faulques, Antonio Maietta, Denis Soulières and Normand Blais

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:22

    Published on:

  36. Content type: Research article

    Prostatic acid phosphatase (PAP) is a prostate tumor antigen, and the target of the only FDA-approved anti-tumor vaccine, sipuleucel-T. We have previously reported in two clinical trials that a DNA vaccine enc...

    Authors: Ellen Wargowski, Laura E. Johnson, Jens C. Eickhoff, Lauren Delmastro, Mary Jane Staab, Glenn Liu and Douglas G. McNeel

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:21

    Published on:

  37. Content type: Research article

    While immune checkpoint blockade has greatly improved clinical outcomes in diseases such as melanoma, there remains a need for predictive biomarkers to determine who will likely benefit most from which therapy...

    Authors: Priyanka B. Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, Anita Giobbie-Hurder, Mariano Severgnini, Jun Zhou, Michael Manos, Lauren M. Eastman, Holden T. Maecker and F. Stephen Hodi

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:18

    Published on:

  38. Content type: Research article

    Immuno-oncology and cancer immunotherapies are areas of intense research. The numbers and locations of CD8+ tumor-infiltrating lymphocytes (TILs) are important measures of the immune response to cancer with pr...

    Authors: Keith E. Steele, Tze Heng Tan, René Korn, Karma Dacosta, Charles Brown, Michael Kuziora, Johannes Zimmermann, Brian Laffin, Moritz Widmaier, Lorenz Rognoni, Ruben Cardenes, Katrin Schneider, Anmarie Boutrin, Philip Martin, Jiping Zha and Tobias Wiestler

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:20

    Published on:

  39. Content type: Research article

    Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient’...

    Authors: Robert O. Dillman, Andrew N. Cornforth, Gabriel I. Nistor, Edward F. McClay, Thomas T. Amatruda and Carol Depriest

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:19

    Published on:

  40. Content type: Research article

    BTH1677, a beta-glucan pathogen-associated molecular pattern molecule, drives an anti-cancer immune response in combination with oncology antibody therapies. This phase II study explored the efficacy, pharmaco...

    Authors: Walburga Engel-Riedel, Jamie Lowe, Paulette Mattson, J. Richard Trout, Richard D. Huhn, Michele Gargano, Myra L. Patchen, Richard Walsh, My My Trinh, Mariève Dupuis and Folker Schneller

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:16

    Published on:

  41. Content type: Research article

    Numerous oncology combination therapies involving modulators of the cancer immune cycle are being developed, yet quantitative simulation models predictive of outcome are lacking. We here present a model-based ...

    Authors: Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Helen Tomkinson, Nidal Al-Huniti, Donald R. Stanski and Gabriel Helmlinger

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:17

    Published on:

  42. Content type: Research article

    The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. Objectives: 1- Design a sliding scale to grade survival in...

    Authors: Helmy M. Guirgis

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:15

    Published on:

  43. Content type: Case report

    Immune checkpoint therapy has dramatically changed the landscape of cancer therapy, providing an efficacious and durable therapeutic option for patients with advanced-stage disease. However, dermatologic toxic...

    Authors: Michael T. Tetzlaff, Kelly C. Nelson, Adi Diab, Gregg A. Staerkel, Priyadharsini Nagarajan, Carlos A. Torres-Cabala, Beth A. Chasen, Jennifer A. Wargo, Victor G. Prieto, Rodabe N. Amaria and Jonathan L. Curry

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:14

    Published on:

  44. Content type: Case report

    Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent therapy like surgery and radiation, fifty percent of ...

    Authors: Muhammad Zubair Afzal, Rodwell Mabaera and Keisuke Shirai

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:13

    Published on:

  45. Content type: Case report

    Immune check point inhibitors (ICIs) have emerged as a new therapeutic paradigm for a variety of malignancies including metastatic melanoma. As the use of ICIs expand, immune-mediated adverse events are becomi...

    Authors: Amrita Padda, Elena Schiopu, Justin Sovich, Vincent Ma, Ajjai Alva and Leslie Fecher

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:12

    Published on:

  46. Content type: Research article

    Immuno-oncotherapy has emerged as a promising means to target cancer. In particular, therapeutic manipulation of tumor-associated macrophages holds promise due to their various and sometimes opposing roles in ...

    Authors: Grace Mahlbacher, Louis T. Curtis, John Lowengrub and Hermann B. Frieboes

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:10

    Published on:

  47. Content type: Case report

    Ipilimumab is an FDA-approved anti-CTLA-4 monoclonal antibody used in treatment of metastatic melanoma. We present an unusual neurological complication of Ipilimumab therapy and the diagnostic dilemma it caused.

    Authors: Lorraine Cafuir, David Lawson, Nilesh Desai, Vita Kesner and Alfredo Voloschin

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:11

    Published on:

  48. Content type: Meeting report

    Radiotherapy (RT) has been a fundamental component of the anti-cancer armamentarium for over a century. Approximately half of all cancer patients are treated with radiotherapy during their disease course. Over...

    Authors: Ariel E. Marciscano, Joshua M. Walker, Heather M. McGee, Michelle M. Kim, Charles A. Kunos, Arta M. Monjazeb, Stephen L. Shiao, Phuoc T. Tran and Mansoor M. Ahmed

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:6

    Published on:

  49. Content type: Research article

    Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remain...

    Authors: Vadim S. Koshkin, Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, Sumanta K. Pal, JoAnn Hsu, Leonard J. Appleman, Moshe C. Ornstein, Timothy Gilligan, Petros Grivas, Jorge A. Garcia and Brian I. Rini

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:9

    Published on:

2017 Journal Metrics

Advertisement